title: [Improved therapeutic effectiveness by combining recombinant human RhoB with low-dose cisplatin in human lung cancer in nude mice].
abstract: OBJECTIVE
  To determine the antitumor effects of the recombinant human RhoB with low-dose cisplatin in lung carcinoma models.
  
  
  METHODS
  The pVITRO2-RhoB recombinant was constructed and transfected into A549 cells. Its expression and the inhibition effect to the A549 cells were observed models. A549 lung carcinoma mice were treated with either RhoB or cisplatin or both agents together. And the change of tumor size, the survive time of mice, the apoptosis of tumor were also observed.
  
  
  RESULTS
  The pVITRO2-RhoB recombinant was constructed successfully. This recombinant could inhibit the growth and promote the apoptosis of A594 in vitro. Mice treated with RhoB or low-dose cisplatin treatment individually resulted in tumor inhibition to a certain extent. Mice treated with combination of RhoB and low-dose cisplatin resulted in synergistic antitumor activity with more effective tumor inhibition (P < 0.05) and longer survival (P < 0.05). TUNEL analysis of tumors exhibited that RhoB in combination with cisplatin led to the increased rate of apoptosis (P < 0.05).
  
  
  CONCLUSIONS
  Our data demonstrated that RhoB could increase the sensitivity of lung carcinoma to cisplatin, resulting in enhanced anti-tumor activity. These results suggest that combination with recombinant human RhoB with chemotherapy drugs may be an effective approach in the treatment of lung carcinoma.
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Hu
authors.forename: Wen-Fang
authors.initials: WF
authors.lastname: Wu
authors.forename: Yong
authors.initials: Y
authors.lastname: Qing
authors.forename: Li-Fang
authors.initials: LF
authors.lastname: Song
authors.forename: Wen
authors.initials: W
authors.lastname: Huang
authors.forename: Yang
authors.initials: Y
authors.lastname: Wu
authors.forename: Yi
authors.initials: Y
authors.lastname: Li
authors.forename: Xiao-Hua
authors.initials: XH
authors.lastname: Wu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000627:therapeutic use*; D020743:rhoB GTP-Binding Protein / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D020743:rhoB GTP-Binding Protein; D002945:Cisplatin